keyword
MENU ▼
Read by QxMD icon Read
search

golimumab

keyword
https://www.readbyqxmd.com/read/29140944/subcutaneous-golimumab-in-pediatric-ulcerative-colitis-pharmacokinetics-and-clinical-benefit
#1
Jeffrey S Hyams, Daphne Chan, Omoniyi J Adedokun, Lakshmi Padgett, Dan Turner, Anne Griffiths, Genevieve Veereman, Melvin B Heyman, Joel R Rosh, Ghassan Wahbeh, Richard Strauss
BACKGROUND: Current treatments for pediatric ulcerative colitis (UC) are limited. We evaluated the pharmacokinetics and clinical benefits of subcutaneous golimumab, an anti-tumor necrosis factor agent, in moderately-to-severely active pediatric patients with UC refractory to conventional therapy. METHODS: We report a multicenter, open-label study of golimumab with a pharmacokinetics phase (week 0-14). Patients had moderately-to-severely active UC and were naive to anti-tumor necrosis factor treatment...
December 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29127626/impact-of-infliximab-and-etanercept-biosimilars-on-biological-disease-modifying-antirheumatic-drugs-utilisation-and-nhs-budget-in-the-uk
#2
Mohammed I Aladul, Raymond W Fitzpatrick, Stephen R Chapman
OBJECTIVE: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective but expensive options for treating rheumatoid arthritis. The introduction of infliximab and etanercept biosimilars presents a significant potential cost saving in a financially constrained health system such as the National Health Service (NHS) in the UK. This study examines the impact of the introduction of infliximab and etanercept biosimilars on the utilisation of bDMARDs and subsequent budget impact...
November 10, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29082659/two-year-persistence-of-golimumab-as-second-line-biologic-agent-in-rheumatoid-arthritis-as-compared-to-other-subcutaneous-tumor-necrosis-factor-inhibitors-real-life-data-from-the-lorhen-registry
#3
Ennio G Favalli, Luigi Sinigaglia, Andrea Becciolini, Vittorio Grosso, Roberto Gorla, Chiara Bazzani, Fabiola Atzeni, Pier C Sarzi Puttini, Enrico Fusaro, Raffaele Pellerito, Roberto Caporali
OBJECTIVES: To evaluate the 2-year retention rate of golimumab compared with etanercept and adalimumab as second-line biologic agent in rheumatoid arthritis (RA) patients who failed a previous tumor necrosis factor inhibitor (TNFi). METHODS: Data on RA patients treated with a second-line subcutaneous TNFi were extracted from a multicentric Italian cohort (the LORHEN registry). The analysis was limited to etanercept, adalimumab and golimumab in the period when all were available in Italy (since October 2010)...
October 30, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29081616/biological-response-modifiers-in-rheumatoid-arthritis-systematic-review-and-meta-analysis-of-safety
#4
Nitishkumar D Tank, Bharti N Karelia, Bhavisha N Vegada
OBJECTIVE: To analyze available evidence on the safety of different biological response modifiers which are used for a treatment of rheumatoid arthritis (RA). MATERIALS AND METHODS: We searched systematically for randomized controlled clinical trials on treatment of RA with different biological response modifiers, followed by a systematic review with meta-analysis. Trials were searched from MEDLINE and Cochrane Library databases. The following safety parameters reported in the selected trials were analyzed: number of patients suffering any adverse event (AE), withdrawal due to AEs, serious AE (SAEs), infections, serious infections, infusion reactions, injection site reactions, malignancies, and overall mortality...
July 2017: Journal of Pharmacology & Pharmacotherapeutics
https://www.readbyqxmd.com/read/29075910/pyoderma-gangrenosum-and-pyogenic-arthritis-presenting-as-severe-sepsis-in-a-rheumatoid-arthritis-patient-treated-with-golimumab
#5
REVIEW
Anastasia Skalkou, Sofia-Magdalini Manoli, Alexandros Sachinidis, Vasilios Ntouros, Konstantinos Petidis, Eleni Pagkopoulou, Efstratios Vakirlis, Athina Pyrpasopoulou, Theodoros Dimitroulas
Rheumatoid arthritis is a systemic autoimmune disease resulting in joint destruction and deformities, but also associated with extraarticular and systemic manifestations. The later devastating conditions, such as the development of rheumatoid vasculitis, are more frequently encountered in seropositive patients and their incidence has been attenuated after the introduction of biologic disease modifying drugs, such as anti-tumor necrosis factor alpha (TNFa) agents, which generally have considerably contributed to the better control and long-term outcomes of the disease...
October 26, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29050449/doubling-golimumab-doses-did-not-improve-skin-disease-in-two-obese-patients-with-psoriatic-arthritis
#6
Claudio Bonifati, Viviana Lora, Dario Graceffa
No abstract text is available yet for this article.
December 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29049193/efficacy-and-safety-of-immunomodulatory-drugs-in-patients-with-anterior-uveitis-a-systematic-literature-review
#7
REVIEW
Alejandro Gómez-Gómez, Estíbaliz Loza, Maria Piedad Rosario, Gerard Espinosa, José M García Ruiz de Morales, Jose M Herreras, Santiago Muñoz-Fernández, Miguel Cordero-Coma
BACKGROUND: To assess the efficacy and safety of immunomodulatory drugs in patients with noninfectious anterior uveitis (AU). METHODS: Systematic review of studies were retrieved from Medline (1961 to March 2016), Embase (1961 to March 2016), and Cochrane Library (up to March 2016), and a complementary hand search was also performed. The selection criteria were as follows: (population) noninfectious AU patients, adults; (intervention) immunomodulatory drugs (any dose, regimen, route of administration, duration of treatment); (outcome) control of inflammation, steroid-sparing effect, AU flares, adverse events, and so on; (study design) systematic literature reviews, randomized controlled trials, and observational studies...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29039054/treatment-persistence-and-healthcare-costs-among-patients-with-rheumatoid-arthritis-changing-biologics-in-the-usa
#8
Benjamin Chastek, Chieh-I Chen, Clare Proudfoot, Shraddha Shinde, Andreas Kuznik, Wenhui Wei
INTRODUCTION: After a patient with rheumatoid arthritis (RA) fails tumor necrosis factor inhibitor (TNFi) treatment, clinical guidelines support either cycling to another TNFi or switching to a different mechanism of action (MOA), but payers often require TNFi cycling before they reimburse switching MOA. This study examined treatment persistence, cost, and cost per persistent patient among MOA switchers versus TNFi cyclers. METHODS: This study of Commercial and Medicare Advantage claims data from the Optum Research Database included patients with RA and at least one claim for a TNFi (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab) between January 2012 and September 2015 who changed to another TNFi or a different MOA therapy (abatacept, tocilizumab, or tofacitinib) within 1 year...
October 16, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29027693/efficacy-and-safety-of-golimumab-in-crohn-s-disease-a-french-national-retrospective-study
#9
C Martineau, B Flourié, P Wils, T Vaysse, R Altwegg, A Buisson, A Amiot, G Pineton de Chambrun, V Abitbol, M Fumery, X Hébuterne, S Viennot, D Laharie, L Beaugerie, S Nancey, H Sokol
BACKGROUND: Anti-tumour necrosis factor (TNF) agents have improved the care of Crohn's disease (CD). After the first anti-TNF discontinuation, it is possible to switch to another anti-TNF. Three anti-TNF agents are available for ulcerative colitis (infliximab, adalimumab and golimumab), but only the first 2 have been approved for CD because golimumab has not been studied for this indication. AIM: To report the efficacy and safety of golimumab in CD. METHODS: Crohn's disease patients who received golimumab were identified in 12 French tertiary centres and were retrospectively analysed...
October 13, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29022668/erratum
#10
(no author information available yet)
This erratum corrects information regarding golimumab in table 6 for article [Management of ulcerative colitis in 2017], PMID: 28853805.
October 11, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28981395/rapid-and-sustained-efficacy-of-golimumab-in-the-treatment-of-multirefractory-uveitis-associated-with-beh%C3%A3-et-s-disease
#11
Claudia Fabiani, Jurgen Sota, Donato Rigante, Antonio Vitale, Giacomo Emmi, Lorenzo Vannozzi, Rossella Franceschini, Daniela Bacherini, Bruno Frediani, Mauro Galeazzi, Gian Marco Tosi, Luca Cantarini
PURPOSE: To evaluate golimumab (GOL) efficacy in the management of Behçet's disease (BD)-related uveitis. METHODS: We retrospectively collected data from 5 patients (8 eyes) with at least two recent relapses of uveitis, treated with GOL at the standard dose of 50 mg every 4 weeks. RESULTS: A complete control of intraocular inflammation was observed in 7/8 eyes (87.5%) at 12-month follow-up. The number of relapses 12 months before and after GOL initiation was 11 and 1, respectively...
October 5, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28980904/optimal-concentration-range-of-golimumab-in-patients-with-axial-spondyloarthritis
#12
Ana Martínez-Feito, Chamaida Plasencia-Rodriguez, Victoria Navarro-Compán, Teresa Jurado, Eva Linda Kneepkens, Gertjan J Wolbink, Sergio Martín, Ainhoa Ruiz Del Agua, Rosaura Navarro, Araceli Mezcua, Andrea Jochems, Diana Peiteado, Maria Gema Bonilla, Alejandro Balsa, Dora Pascual-Salcedo
OBJECTIVES: To investigate the association between serum golimumab (GLM) trough levels, clinical disease activity and treatment response during the first year of therapy in patients with axial spondyloarthritis (axSpA), as well as determining an optimal concentration range of GLM in axSpA. METHODS: This was an observational prospective study including 49 patients with axSpA monitored during 52 weeks (W52). Serum GLM trough levels were measured by capture ELISA and antidrug antibodies by bridging ELISA at baseline, W24 and W52...
September 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28975392/second-line-treatment-persistence-and-costs-among-patients-with-immune-mediated-rheumatic-diseases-treated-with-subcutaneous-tnf-alpha-inhibitors
#13
Johan Dalén, Axel Svedbom, Christopher M Black, Sumesh Kachroo
The objective of this study was to describe treatment persistence with second-line subcutaneous tumor necrosis factor-alpha inhibitors (SC-TNFis) in patients with immune-mediated rheumatic diseases (IMRDs) in Sweden, and the impact of non-persistence on healthcare costs. This retrospective observational study was based on Swedish national health register data. Adults were identified through filled prescriptions for adalimumab (ADA), etanercept (ETA), certolizumab pegol (CZP) and golimumab (GLM). Persistence was estimated over 3 years for propensity score-matched (PSM) cohorts using non-parametric survival analysis...
December 2017: Rheumatology International
https://www.readbyqxmd.com/read/28956301/cost-effectiveness-of-golimumab-in-ankylosing-spondylitis-from-the-uk-payer-perspective
#14
Rebekah H Borse, Chloe Brown, Noemi Muszbek, Mohammad Ashraf Chaudhary, Sumesh Kachroo
INTRODUCTION: Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study evaluated the cost-effectiveness of golimumab compared with conventional care and other TNF-α inhibitors in treatment of AS from the UK National Health Service perspective. METHODS: A long-term Markov model (with initial decision tree) was developed to simulate the progression of a hypothetical cohort of patients with active AS over a lifetime...
September 27, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28945143/cost-effectiveness-analysis-of-secukinumab-for-the-treatment-of-active-psoriatic-arthritis-a-canadian-perspective
#15
Ron Goeree, Sima Chiva-Razavi, Praveen Gunda, Christopher N Graham, LaStella Miles, Efthalia Nikoglou, Steffen M Jugl, Dafna Gladman
OBJECTIVE: The study evaluates the cost-effectiveness of secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A, versus currently licensed biologic treatments in patients with active psoriatic arthritis (PsA) from a Canadian healthcare system perspective. METHODS: A decision analytic semi-Markov model evaluated the cost-effectiveness of secukinumab 150mg and 300mg compared to subcutaneous biologics adalimumab, certolizumab pegol, etanercept, golimumab, and ustekinumab and intravenous biologics infliximab and infliximab biosimilar in biologic-naive and biologic-experienced patients over a lifetime horizon...
September 25, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28941039/a-randomized-phase-iib-study-of-mavrilimumab-and-golimumab-in-rheumatoid-arthritis
#16
Michael E Weinblatt, Iain B McInnes, Joel M Kremer, Pedro Miranda, Jiri Vencovsky, Xiang Guo, Wendy I White, Patricia C Ryan, Alex Godwood, Marius Albulescu, David Close, Gerd R Burmester
OBJECTIVE: This 24-week, Phase IIb, double-blind study (NCT01715896) evaluated mavrilimumab (anti-granulocyte-macrophage colony-stimulating factor [GM-CSFR]-α monoclonal antibody) and golimumab (anti-tumor necrosis factor [TNF] monoclonal antibody) in patients with rheumatoid arthritis (RA), with inadequate responses to disease-modifying antirheumatic drugs (DMARD-IR) and/or anti-TNF agents (anti-TNF-IR). METHODS: Patients with active RA and DMARD-IR (≥1 failed regimen), or DMARD-IR (≥1 failed regimen) and anti-TNF-IR (1-2 failed regimens), were randomized 1:1 to subcutaneous mavrilimumab 100 mg every other week (eow) or golimumab 50 mg every 4 weeks (Q4W) alternating with placebo Q4W, plus concomitant methotrexate...
September 21, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28928177/adherence-and-dosing-interval-of-subcutaneous-antitumour-necrosis-factor-biologics-among-patients-with-inflammatory-arthritis-analysis-from-a-canadian-administrative-database
#17
Peter Bhoi, Louis Bessette, Mary J Bell, Cathy Tkaczyk, Francois Nantel, Karina Maslova
OBJECTIVES: Subcutaneous tumour necrosis factor alpha TNFαinhibitors (SC-TNFis) such as golimumab (GLM), adalimumab (ADA), etanercept (ETA) and certolizumab pegol (CZP) have been used for many years for the treatment of inflammatory arthritis. Non-adherence to therapy is an important modifiable factor that may compromise patient outcomes. The aim of this analysis was to compare adherence and dosing interval of SC-TNFis in the treatment of people with inflammatory arthritis. DESIGN: We used the IMS Brogan database combining both Canadian private and public drug plan databases of Ontario and Quebec...
September 18, 2017: BMJ Open
https://www.readbyqxmd.com/read/28922435/effectiveness-and-safety-of-golimumab-in-treating-outpatient-ulcerative-colitis-a-real-life-prospective-multicentre-observational-study-in-primary-inflammatory-bowel-diseases-centers
#18
Antonio Tursi, Leonardo Allegretta, Nello Buccianti, Nicola Della Valle, Walter Elisei, Giacomo Forti, Roberto Faggiani, Sara Gallina, Yusef Hadad, Tiziana Larussa, Angelo Lauria, Francesco Luzza, Roberto Lorenzetti, Giammarco Mocci, Antonio Penna, Natale Polimeni, Giuseppe Pranzo, Cristina Ricciardelli, Costantino Zampaletta, Marcello Picchio
BACKGROUND AND AIMS: Golimumab (GOL) has been recently approved in Italy for the treatment of ulcerative colitis (UC) unresponsive to standard treatments. Our aims were to assess the real-life efficacy and safety of GOL in managing UC outpatients in Italian primary Inflammatory Bowel Diseases (IBD) centres. METHODS: Consecutive UC outpatients with at least 3-months follow-up were enrolled. Primary end-point was the induction and maintenance of remission in UC, defined as Mayo score </=2, at 6-month follow-up...
September 2017: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/28906290/safety-considerations-with-the-use-of-corticosteroids-and-biologic-therapies-in-mild-to-moderate-ulcerative-colitis
#19
Raymond K Cross
BACKGROUND: The risk of corticosteroid-associated adverse events can limit the use of systemic corticosteroids. Oral, topically acting, second-generation corticosteroids that deliver drug to the site of inflammation, and biologic therapies, are effective treatment alternatives. The aim of this review was to evaluate the safety and tolerability of topically acting corticosteroids and biologic therapies versus oral systemic corticosteroids for ulcerative colitis (UC). METHODS: The PubMed database was searched for clinical and observational trials, systematic reviews, and case reports/series published between January 1950 and September 30, 2016...
October 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28905859/clinical-trials-intravenous-golimumab-effective-for-psa
#20
Sarah Onuora
No abstract text is available yet for this article.
October 2017: Nature Reviews. Rheumatology
keyword
keyword
19896
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"